 Interferon-alpha
"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.644.276.718.500.250 D12.776.467.374.440.890.250 D12.776.467.718.500.250 D23.529.374.440.890.250 D23.529.718.500.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- Interferon Alfa
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Leukocyte
- Leukocyte Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- alpha-Interferon
- alpha Interferon
- Interferon, alpha
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- LeIF A
- Interferon alpha-A
- Interferon alpha A
- Interferon-alpha 2
- 2, Interferon-alpha
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 2 | 0 | 2 | | 1991 | 0 | 1 | 1 | | 1992 | 3 | 0 | 3 | | 1993 | 2 | 0 | 2 | | 1994 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 1 | 3 | 4 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 3 | 5 | | 2008 | 4 | 2 | 6 | | 2009 | 3 | 1 | 4 | | 2010 | 2 | 5 | 7 | | 2011 | 4 | 2 | 6 | | 2012 | 4 | 2 | 6 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Walker CJ, Espinosa ML, Mehta-Shah N, Pro B, Guitart J, Kuzel T. Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides. J Drugs Dermatol. 2021 03 01; 20(3):349-350.
-
Doyle EH, Rahman A, Aloman C, Klepper AL, El-Shamy A, Eng F, Rocha C, Kim S, Haydel B, Florman SS, Fiel MI, Schiano T, Branch AD. Individual liver plasmacytoid dendritic cells are capable of producing IFNa and multiple additional cytokines during chronic HCV infection. PLoS Pathog. 2019 07; 15(7):e1007935.
-
Hamidi O, Reiser J, Hasler S. An Interferon-Induced Digital Vasculitis-Like Syndrome: A Case Report. Am J Ther. 2016 May-Jun; 23(3):e920-5.
-
Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49.
-
Bayat A, Burbelo PD, Browne SK, Quinlivan M, Martinez B, Holland SM, Buvanendran A, Kroin JS, Mannes AJ, Breuer J, Cohen JI, Iadarola MJ. Anti-cytokine autoantibodies in postherpetic neuralgia. J Transl Med. 2015 Oct 20; 13:333.
-
Welch NM, Jensen DM. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7.
-
Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Eng S, Lim CY, Shulman NS, Yetzer ES. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
-
Jolly M, Francis S, Aggarwal R, Mikolaitis RA, Niewold TB, Chubinskaya S, Block JA, Scanzello C, Sequeira W. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus. 2014 Aug; 23(9):881-8.
-
Marcellin P, Craxi A, Brandao-Mello CE, Di Bisceglie AM, Andreone P, Freilich B, Rajender Reddy K, Olveira Martín A, Teuber G, Messinger D, Hooper G, Wat C, Tatsch F, Jensen DM. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93.
-
Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|